Matinas BioPharma
MTNB
57 hedge funds and large institutions have $13.6M invested in Matinas BioPharma in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
4% more funds holding
Funds holding: 55 → 57 (+2)
0.01% less ownership
Funds ownership: 0.26% → 0.25% (-0.01%)
24% less capital invested
Capital invested by funds: $18M → $13.6M (-$4.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$159K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$118K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
| 4 |
GRP
Global Retirement Partners
San Rafael,
California
|
+$92.5K |
| 5 |
VF
Virtu Financial
New York
|
+$78.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.04M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$66.5K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$63K |
| 4 |
MA
MONECO Advisors
Fairfield,
Connecticut
|
-$19K |
| 5 |
GAA
Global Assets Advisory
Orlando,
Florida
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
51
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
SPIA
52
Steward Partners Investment Advisory
New York
| $1.52K | – | – | – |
|
|
EWA
53
EverSource Wealth Advisors
Birmingham,
Alabama
| $1.5K | +$2K | +60 | New |
|
|
HFM
54
Hartford Financial Management
Hartford,
Connecticut
| $1.25K | – | – | – |
|
55
Bank of America
Charlotte,
North Carolina
| $466 | -$466 | -14 | -42% |
|
56
Citigroup
New York
| $90 | – | – | – |
|
57
BNP Paribas Financial Markets
Paris,
France
| $40 | +$67 | +2 | New |
|
|
58
Balyasny Asset Management
Chicago,
Illinois
| – | -$63K | -1,982 | Closed |
|
|
MA
59
MONECO Advisors
Fairfield,
Connecticut
| – | -$19K | -600 | Closed |
|
|
GAA
60
Global Assets Advisory
Orlando,
Florida
| – | -$14K | -365 | Closed |
|
|
SG
61
StoneX Group
New York
| – | -$8.84K | -278 | Closed |
|
|
BJL
62
Brighton Jones LLC
Seattle,
Washington
| – | -$6K | -200 | Closed |
|
MTNB Hedge Fund Activity: Q4 2022 in Review
57 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2022, worth a combined $13.6M — down 24% from $18M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MTNB positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $159K. The largest seller was BlackRock, cutting an estimated $1.04M.
- 57 institutional investors held Matinas BioPharma (MTNB) as of Q4 2022, up from 55 in Q3 2022.
- Funds reported $13.6M of Matinas BioPharma stock for Q4 2022, down 24% quarter-over-quarter.
- 9 funds opened new Matinas BioPharma positions in Q4 2022 and 6 closed out, a net change of +3 holders.
- The largest Matinas BioPharma buyer in Q4 2022 was Millennium Management, an estimated $159K added.
- The largest Matinas BioPharma seller in Q4 2022 was BlackRock, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2022.